Pandemic News and Research

RSS

A pandemic is a global disease outbreak. During a pandemic, transmission can be anticipated in the workplace, not only from patient to workers in health care settings, but also among co-workers in general work settings. A pandemic would cause high levels of illness, death, social disruption, and economic loss. Everyday life would be disrupted because so many people in so many places become seriously ill at the same time. Impacts could range from school and business closings to the interruption of basic services such as public transportation and food delivery.

NIH launches trial for the determination of 2009 H1N1 influenza vaccine for asthma patients

The National Institutes of Health is preparing to launch the first government-sponsored clinical trial to determine what dose of the 2009 H1N1 influenza vaccine is needed to induce a protective immune response in people with asthma, especially those with severe disease.

12 Oct 2009

A three-month study reveals the impact of swine flu on the health of the general public in Australia and New Zealand

A comprehensive study has revealed, for the first time, the impact of swine flu on the health of the general public in Australia and New Zealand.

9 Oct 2009

Verichip Corporation's H1N1 virus triage detection system to feature in Fox News

VeriChip Corporation has announced that the Company is scheduled to be featured on the Glenn Beck show on Fox News today, October 8, 2009 during the 5 p.m. hour. Glenn Beck intends to dedicate today's show to the H1N1 virus and will feature VeriChip, its Health Link personal health record and its H1N1 virus triage detection system currently being developed with partner RECEPTORS LLC, as part of the show.

9 Oct 2009

Medicago receives contract from U.S. Army Research, Development and Engineering Command laboratory

Medicago Inc. (TSX-V: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has been awarded a proof of concept contract by the U.S. Army Research, Development and Engineering Command laboratory specifically the Edgewood Chemical Biological Center ("ECBC") Research & Technology Directorate.

9 Oct 2009

CytoDyn to conduct a study on Cytolin at Massachusetts General Hospital

In response to new economic and regulatory realities, CytoDyn, Inc. has made a sea change in its strategy for developing Cytolin®, the Company’s unique immune therapy for treating HIV/AIDS.

9 Oct 2009

Series of national television public service advertisements to prevent the spread of H1N1 flu virus

Health and Human Services Secretary Kathleen Sebelius announced today that the Department of Health and Human Services (HHS) is joining with The Ad Council to launch a series of national television public service advertisements (PSAs) designed to encourage Americans to take steps to protect themselves from the 2009 H1N1 flu virus.

9 Oct 2009

Telecommuting is an option for businesses during H1N1 outbreak

Incorporating telecommuting into a business continuity plan helps ensure "business as usual" during a widespread H1N1 outbreak. By giving employees the tools, policies, and procedures necessary to effectively work at home, companies ensure continuity of operations regardless of the ability of personnel to come into a centralized office location; which results in continued customer service, a continued revenue stream, and an ultimate maintenance of customer and brand loyalty.

8 Oct 2009

Global pharmaceutical market to grow by 4 - 6 percent: IMS Health

IMS Health reported today that the value of the global pharmaceutical market in 2010 is expected to grow 4 - 6 percent on a constant-dollar basis, exceeding $825 billion, driven by stronger near-term growth in the U.S. market.

8 Oct 2009

The Prescription Center Pharmacy launches 'Be Prepared, Not Scared' campaign

The Prescription Center Pharmacy, headquartered in Beverly Hills, California announced its “Be Prepared, Not Scared” campaign today. The purpose of the campaign is to help both businesses and consumers stay healthy, without dramatically changing their daily routines. Dr. Afshin Nassir, the pharmacy’s Founder and CEO, states that “We want to help businesses and consumers create a realistic plan to deal with the H1N1 (Swine Flu) Virus, which is now, according to the Center for Disease Control (CDC), at a Pandemic stage.”

8 Oct 2009

WHO emphasizes H1N1 vaccine safety

The WHO on Tuesday continued to express confidence in the H1N1 (swine flu) vaccine as few mild adverse effects have been reported by patients participating in China's vaccine campaign, the Associated Press reports. Out of the 39,000 people in China who received the H1N1 vaccine, four reported experiencing side effects such as muscle cramps and headache, according to WHO spokesman Gregory Hartl (Higgins, 10/6).

8 Oct 2009

Microsoft launches a new online H1N1 Flu Response Center

With the current H1N1 flu (swine flu) pandemic under way, many public health officials are concerned that critical healthcare resources could be stretched thin as people flood hospital emergency departments and physicians' offices to determine whether they have the illness.

7 Oct 2009

Diabetech and Cinterion Wireless Modules announce their collaboration on fourth generation GlucoMON platform

Cinterion Wireless Modules, the global leader in cellular machine-to-machine (M2M) communication modules, and Diabetech, the leader in patient-centric health care programs, today announced their collaboration on the fourth generation GlucoMON® platform, the world’s easiest-to-use wireless diabetes management system designed to help the over 220 million people worldwide struggling to manage the global diabetes and pre-diabetes pandemic.

7 Oct 2009

Baxter receives marketing authorization for CELVAPAN H1N1 pandemic influenza vaccine

Baxter International Inc. today confirmed that the European Commission (EC) has granted marketing authorization for CELVAPAN H1N1 pandemic vaccine using Baxter’s Vero cell technology. CELVAPAN H1N1 is the first cell culture-based and non-adjuvanted pandemic influenza vaccine to receive marketing authorization in the European Union.

From Baxter International Inc. 7 Oct 2009

Autism rates among U.S. children is one in 91, says new report

A new report out yesterday places autism rates among U.S. children at one in 91, with autism now affecting one in 58 boys. These new numbers, from Health Resources and Services Administration (HRSA), U.S. Department of Health and Human Services, are prompting outrage from parents and autism advocates over inaction from government health agencies in addressing the crisis affecting hundreds of thousands of American families.

7 Oct 2009

Swine Flu vaccine arrives as flu moves quickly through population

The first doses of Swine Flu have arrived in the United States, as health officials work quickly to inoculate people against the virus.

7 Oct 2009

Pennsylvania to receive first doses of live attenuated pandemic H1N1 influenza vaccine

Pre-registered and certified providers in the southwest, southeast, and north-central regions of the state have begun to receive the first doses of the live attenuated pandemic H1N1 influenza vaccine, also known by the brand name FluMist, the Pennsylvania Department of Health said today.

7 Oct 2009

New cases of H1N1 worldwide up 24,000 in two weeks

The number of H1N1 (swine flu) cases reported in WHO regions worldwide has grown by at least 24,000 in two weeks to cross the 340,000 mark since the virus was first detected in mid-April, the CDC reported Monday, according to Agence France-Presse.

7 Oct 2009

Measures taken by Memorial Blood Centers to stay prepared for the spread of H1N1 virus

Memorial Blood Centers today outlined steps the organization is taking to stay prepared for the spread of the H1N1 virus and to ensure a safe experience for blood donors and an ample blood supply for our communities.

7 Oct 2009

Vivaldi receives US patent for live attenuated influenza vaccines

Vivaldi Biosciences Inc. (Vivaldi), a biotechnology company focused on development of vaccines for influenza, today announced that the United States Patent and Trademark Office has issued US Patent 7,588,768 covering live attenuated influenza vaccines (LAIVs) with modifications to the viral NS1 gene, and methods for producing the vaccines in cell culture systems.

6 Oct 2009

Majority of Europeans not concerned about H1N1

Three quarters of European people surveyed between the 30th April and 6th May 2009 said they were either not at all concerned or only a little concerned about swine flu.

6 Oct 2009

Pandemic News and Research

Further Reading

NIH launches trial for the determination of 2009 H1N1 influenza vaccine for asthma patients

A three-month study reveals the impact of swine flu on the health of the general public in Australia and New Zealand

Verichip Corporation's H1N1 virus triage detection system to feature in Fox News

Medicago receives contract from U.S. Army Research, Development and Engineering Command laboratory

CytoDyn to conduct a study on Cytolin at Massachusetts General Hospital

Series of national television public service advertisements to prevent the spread of H1N1 flu virus

Telecommuting is an option for businesses during H1N1 outbreak

Global pharmaceutical market to grow by 4 - 6 percent: IMS Health

The Prescription Center Pharmacy launches 'Be Prepared, Not Scared' campaign

WHO emphasizes H1N1 vaccine safety

Microsoft launches a new online H1N1 Flu Response Center

Diabetech and Cinterion Wireless Modules announce their collaboration on fourth generation GlucoMON platform

Baxter receives marketing authorization for CELVAPAN H1N1 pandemic influenza vaccine

Autism rates among U.S. children is one in 91, says new report

Swine Flu vaccine arrives as flu moves quickly through population

Pennsylvania to receive first doses of live attenuated pandemic H1N1 influenza vaccine

New cases of H1N1 worldwide up 24,000 in two weeks

Measures taken by Memorial Blood Centers to stay prepared for the spread of H1N1 virus

Vivaldi receives US patent for live attenuated influenza vaccines

Majority of Europeans not concerned about H1N1

Best practices - optimize qPCR processes for pathogen detection eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News